RYBODYN JOINS NVIDIA INCEPTION TO ADVANCE AI-POWERED DISCOVERY OF THE DARK PROTEOME
RyboDyn Joins NVIDIA Inception to Advance AI-Powered Discovery of the Dark Proteome.
RYBODYN FEATURED IN UNION-TRIBUNE AS LILLY GATEWAY LABS OPENS IN SAN DIEGO
RyboDyn is honored to be featured in the San Diego Union-Tribune for Lilly and Company Gateway Labs opening.
RYBODYN SELECTED TO JOIN LILLY GATEWAY LABS TO ADVANCE NEXT-GEN IMMUNOTHERAPIES TARGETING THE DARK PROTEOME
Lilly Collaboration Accelerates RyboDyn’s Dark Proteome Targets Toward First-in-Class Therapies
RYBODYN EXPANDS STRATEGIC CANCER IMMUNOTHERAPY COLLABORATION WITH MOFFITT CANCER CENTER
RyboDyn Expands Strategic Cancer Immunotherapy Collaboration with Moffitt Cancer Center
RYBODYN ANNOUNCES DISCOVERY OF CRYPTIC HUMAN PROTEOME AND $4M PRE-SEED FINANCING
RyboDyn, Inc. Announces Discovery of a Cryptic Human Proteome and $4M Pre-Seed Financing